EA
MRNA icon

Evolution Advisers’s Moderna MRNA Stock Holding History

Evolution Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+4
New +$207 ﹤0.01% 626

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Evolution Advisers's MRNA Position: Q2 2026 in Review

Evolution Advisers opened a new position in Moderna (MRNA) in Q2 2026: 4 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #626 among its holdings.

775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Evolution Advisers held 4 shares of Moderna worth $0 as of Q2 2026.
  • Moderna was a new Evolution Advisers position in Q2 2026.
  • Moderna made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #626 holding.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.